An outbreak of serotype-1 sequence type 306 invasive pneumococcal disease in an Australian Indigenous population

Authors

  • Heather M Cook Enhanced Invasive Pneumococcal Disease Surveillance Working Group ;Centre for Disease Control, Top End Health Services, Northern Territory, Australia
  • Carolien M Giele Enhanced Invasive Pneumococcal Disease Surveillance Working Group;Communicable Diseases Control, Health Department of Western Australia, Australia
  • Sanjay H Jayasinghe Enhanced Invasive Pneumococcal Disease Surveillance Working Group;Discipline of Child and Adolescent Health, Faculty of Medicine and Health, University of Sydney, Australia ;Communicable Diseases Branch, Queensland Health, Australia
  • Angela Wakefield Enhanced Invasive Pneumococcal Disease Surveillance Working Group;Communicable Diseases Branch, Queensland Health, Australia
  • Vicki L Krause Enhanced Invasive Pneumococcal Disease Surveillance Working Group ;Centre for Disease Control, Top End Health Services, Northern Territory, Australia

DOI:

https://doi.org/10.33321/cdi.2020.44.66

Keywords:

outbreak, serotype-1, invasive pneumococcal disease, Australian Indigenous, pneumococcal vaccine, Streptococcus pneumoniae

Abstract

Between 2010 and 2013, an outbreak of serotype-1 sequence type 306 (ST306) invasive pneumococcal disease (IPD) occurred primarily in remote locations of Northern and Central Australia. This is a descriptive study of the epidemiology of the outbreak using nationwide IPD surveillance data, supplemented with more detailed data held by affected jurisdictions, and of the response to the outbreak, including vaccination strategies. In the year the outbreak peaked (2011), serotype-1 IPD incidence was over 30-fold higher in the affected regions than in the rest of Australia (incidence rate ratio: 30.7 [95% CI 20.1–48.9]). The study includes 245 cases of serotype-1 IPD from the outbreak regions, with 75.5% identified as Indigenous.

No reported cases of serotype-1 IPD occurred in young children who had completed either a 10- or 13-valent pneumococcal conjugate vaccine schedule. However serotype-1 IPD did occur in older children who had previously received 23-valent pneumococcal polysaccharide vaccine.

Development of public-health-focused national IPD management guidelines, including suitable vaccine strategies for consistent use nationwide, could potentially decrease the duration and intensity of similar outbreaks in the future.

Downloads

Download data is not yet available.

References

Australian Government Department of Health. Pneumococcal disease (invasive) Public dataset. [Online.] Canberra: Australian Government Department of Health; 2019. [Accessed on 24 June 2019.] Available from: http://www9.health.gov.au/cda/source/pub_pneum.cfm.

Krause VL, Reid SJ, Merianos A. Invasive pneumocccal disease in the Northern Territory of Australia, 1994–1998. Med J Aust. 2000;173(S2):S27–31.

National Centre for Immunisation Research and Surveillance (NCIRS). History of immunisation in Australia. [Internet.] Sydney: NCIRS; 2019. [Accessed on 24 June 2019.] Available from: http://ncirs.org.au/health-professionals/history-immunisation-australia.

Torzillo PJ, Hanna JN, Morey F, Gratten M, Dixon J, Erlich J. Invasive pneumococcal disease in central Australia. Med J Aust. 1989;162(4):182–6.

Roche PW, Krause VL, Bartlett M, Coleman D, Cook H, Davis C et al. Invasive pneumococcal disease in Australia, 2004. Commun Dis Intell Q Rep. 2006;30(1):80–92.

Jayasinghe S, Chiu C, Menzies R, Lehmann D, Cook H, Giele C et al. Evaluation of impact of 23 valent pneumococcal polysaccharide vaccine following 7 valent pneumococcal conjugate vaccine in Australian Indigenous children. Vaccine. 2015;33(48):6666–74.

Brueggemann AB, Peto TEA, Crook DW, Butler JC, Kristinsson KG, Spratt BG. Temporal and geographic stability of the serogroup-specific invasive disease potential of Streptococcus pneumoniae in children. J Infect Dis. 2004;190(7):1203–11.

Balsells E, Dagan R, Yildirim I, Gounder PP, Steens A, Muñoz-Almagro C et al. The relative invasive disease potential of Streptococcus pneumoniae among children after PCV introduction: a systematic review and meta-analysis. J Infect. 2018;77(5):368–78.

Hausdorff WP, Feikin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis. 2005;5(2):83–93.

Yeh SH, Gurtman A, Hurley DC, Block SL, Schwartz RH, Patterson S et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics. 2010;126(3):e493–505.

Vesikari T, Wysocki J, Chevallier B, Karvonen A, Czajka H, Arsène JP et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J. 2009;28(4 Suppl):S66–76.

Andrews NJ, Waight PA, Burbidge P, Pearce E, Roalfe L, Zancolli M et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis. 2014;14(9):839–46.

Hammitt LL, Etyang AO, Morpeth SC, Ojal J, Mutuku A, Mturi N et al. Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study. Lancet. 2019;393(10186):2146–54.

Toms C, de Kluyver R, Enhanced Invasive Pneumococcal Disease Surveillance Working Group. Invasive pneumococcal disease in Australia, 2011 and 2012. Commun Dis Intell Q Rep. 2016;40(2):E267–84.

Australian Bureau of Statistics. 3101.0 - Australian Demographic Statistics, Dec 2014. [Internet.] Canberra: Australian Government, Australian Bureau of Statistics, 2015. [Accessed on 10 November 2015.] Available from: http://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/3101.0Dec%202014.

Queensland Health Statistics Unit. Queensland population estimates. [Internet.] Brisbane: Queensland Government Department of Health. Available from: https://qheps.health.qld.gov.au/hsu/infobank/infobank-demography#estimated.

Staples M, Graham RMA, Jennison AV, Ariotti L, Hicks V, Cook H et al. Molecular characterization of an Australian serotype 1 Streptococcus pneumoniae outbreak. Epidemiol Infect. 2015;143(2):325–33.

Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. [Online.] Canberra: Australian Government Department of Health; 2018. [Accessed on 24 June 2019.] Available from: https://immunisationhandbook.health.gov.au/.

DeMaria Jr A, Browne K, Berk SL;Sherwood EJ, McCabe WR. An outbreak of type 1 pneumococcal pneumonia in a men’s shelter. JAMA. 1980;244(13):1446–9.

Mercat A, Nguyen J, Dautzenberg B. An outbreak of pneumococcal pneumonia in two men’s shelters. Chest. 1991;99(1):147–51.

Dagan R, Gradstein S, Belmaker I, Porat N, Siton Y, Weber G et al. An outbreak of Streptococcus pneumoniae serotype 1 in a closed community in southern Israel. Clin Infect Dis. 2000;30(2):319–21.

Proulx JF, Déry S, Jetté LP, Ismaël J, Libman M, De Wals P. Pneumonia epidemic caused by a virulent strain of Streptococcus pneumoniae serotype 1 in Nunavik, Quebec. Can Commun Dis Rep. 2002;28(16):129–31.

Le Hello S, Watson M, Levy M, Marcon S, Brown M, Yvon JF et al. Invasive serotype 1 Streptococcus pneumoniae outbreaks in the South Pacific from 2000 to 2007. J Clin Microbiol. 2010; 48(8):2968-71.

Grau I, Ardanuy C, Calatayud L, Rolo D, Domenech A, Liñares J et al. Invasive pneumococcal disease in healthy adults: increase of empyema associated with the clonal-type Sweden(1)-ST306. PLoS One. 2012;7(8):e42595.

Van Mens SP, Van Deursen AMM, Meijvis SCA, Vlaminckx BJM, Sanders EAM, De Melker HE et al. Increased incidence of serotype-1 invasive pneumococcal disease in young female adults in the Netherlands. Epidemiol Infect. 2014;142(9):1996–9.

Kwambana-Adams BA, Asiedu-Bekoe F, Sarkodie B, Afreh OK, Kuma GK, Owusu-Okyere G et al. An outbreak of pneumococcal meningitis among older children (≥5 years) and adults after the implementation of an infant vaccination programme with the 13-valent pneumococcal conjugate vaccine in Ghana. BMC Infect Dis. 2016;16(1):575.

LeMeur JB, Lefebvre B, Proulx JF, De Wals P. Limited impact of pneumococcal vaccines on invasive pneumococcal disease in Nunavik (Quebec). Can J Public Health. 2019;110(1):36–43.

Gratten M, Morey F, Dixon J, Manning K, Torzillo P, Matters R et al. An outbreak of serotype 1 Streptococcus pneumoniae infection in central Australia. Med J Aust. 1993;158(5):340–2.

Lim E, Heffernan H. Invasive pneumococcal disease in New Zealand, 2011. Porirua: Institute of Environmental Science and Research Ltd; 2012. [Accessed on 26 June 2019.] Available from: https://surv.esr.cri.nz/PDF_surveillance/IPD/2011/2011AnnualIPDRpt.pdf.

Bailie RS, Wayte KJ. Housing and health in Indigenous communities: key issues for housing and health improvement in remote Aboriginal and Torres Strait Islander communities. Aust J Rural Health. 2006;14(5):171–83.

Lai JY, Cook H, Yip TW, Berthelsen J, Gourley S, Krause V et al. Surveillance of pneumococcal serotype 1 carriage during an outbreak of serotype 1 invasive pneumococcal disease in central Australia 2010–2012. BMC Infect Dis. 2013:13:409.

Bright A, Dups J. Infectious and congenital syphilis notifications associated with an ongoing outbreak in northern Australia. Commun Dis Intell Q Rep. 2016;40(1):E7–10.

Australian Government Department of Health. Meningococcal W disease: Information for health professionals. [Online.] Canberra: Australian Government Department of Health; 2017. [Accessed on 17 October 2018.] Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/ohp-meningococcal-W-info-hp.htm.

Greenwood-Smith B, Markey P, Burke J. Mumps outbreak in the Northern Territory 2015–2016. NT Dis Control Bull. 2016;23(4):9-14.

Heffernan H, Morgan J, Woodhouse R. Invasive pneumococcal disease in New Zealand, 2010. Porirua: Institute of Environmental Science and Research Ltd; 2011. [Accessed on 26 June 2019.] Available from: https://surv.esr.cri.nz/PDF_surveillance/IPD/2010/2010AnnualIPDRpt.pdf.

World Health Organisation (WHO). Additional summaries of information related to WHO position papers on pneumococcus: Duration of protection and revaccination. Geneva: WHO. [Accessed on 26 June 2019.] Available from: https://www.who.int/immunization/pp_pneumo_additional_summaries/en/.

Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013;2013(1):CD000422. doi: https://doi.org/10.1002/14651858.CD000422.pub3.

Cook H, Markey P, O’Hare S, Smith HV, Tindall H, Yip TW et al. A lengthy widespread outbreak of serotype-1 invasive pneumococcal disease shows protection with the 10-valent conjugate vaccine and increased pneumonia complications. [Conference presentation.] Proceedings of the 8th International Symposium on Pneumococci and Pneumococcal Diseases, 2012 March 11-15, Iguaçu Falls, Brazil.

Australian Bureau of Statistics. 4727.0.55.002 – Australian Aboriginal and Torres Strait Islander Health Survey: Users’ Guide, 2012–13. [Internet.] Canberra: Australian Government, Australian Bureau of Statistics; 2014. [Accessed on 26 July 2018.] Available from: http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/C6F3BD401EF28FD9CA257CAC000D874E.

Hull BP, Hendry AJ, Dey A, Beard FH, Brotherton JM, McIntyre PB. Immunisation coverage annual report, 2014. Commun Dis Intell Q Rep. 2017;41(1):E68–90.

Australian Government Services Australia. Australian Immunisation Register. [Online.] Canberra: Australian Government Services Australia; 2018. [Accessed on 26 June 2019.] Available from: https://www.servicesaustralia.gov.au/individuals/services/medicare/australian-immunisation-register.

Downloads

Published

15/09/20

How to Cite

Cook, Heather M, Carolien M Giele, Sanjay H Jayasinghe, Angela Wakefield, and Vicki L Krause. 2020. “An Outbreak of Serotype-1 Sequence Type 306 Invasive Pneumococcal Disease in an Australian Indigenous Population ”. Communicable Diseases Intelligence 44 (September). https://doi.org/10.33321/cdi.2020.44.66.

Most read articles by the same author(s)

1 2 > >>